Clinical Trials Browser

Not yet recruiting × Sarcoma × Gastrointestinal × Clear all

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Testicular Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT07389525 2026-02-05

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

Phase EARLY_PHASE1 Not yet recruiting

80 enrolled

DermatologicGastrointestinalSarcoma

Gastrointestinal Neoplasms, Melanoma, Sarcoma, Urogenital Neoplasms

NCT06887673 2025-03-20

Lipid Mediators & Cancer: Montelukast, SPM, and Almonds

Phase EARLY_PHASE1 Not yet recruiting

56 enrolled

CNSGastrointestinalGynecologicSarcoma

Brain Neoplasms, Inflammation, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms

NCT06551896 2024-08-13

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

Phase 2 Not yet recruiting

30 enrolled

BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Carcinoma, Carcinoma, Transitional Cell, Lung Neoplasms, Sarcoma, Stomach Neoplasms

NCT04889742 2023-12-26

HETERERO

Phase 2 Not yet recruiting

110 enrolled

EndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Hyperthermia, Anus Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fever, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Neuroendocrine Tumors

NCT05361954 2023-04-12

Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors

Phase 1 Not yet recruiting

36 enrolled

GastrointestinalSarcoma

Neoplasms, Pancreatic Neoplasms, Sarcoma

Clinical Trials

Navigation Intervention for Adolescent and Young Adult Cancer Survivors

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

Lipid Mediators & Cancer: Montelukast, SPM, and Almonds

Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor

HETERERO

Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors